Harrow (NASDAQ:HROW) Stock Price Down 5.1% - Should You Sell?

Harrow, Inc. (NASDAQ:HROW - Get Free Report)'s stock price traded down 5.1% during mid-day trading on Wednesday . The company traded as low as $30.25 and last traded at $30.15. 33,546 shares were traded during trading, a decline of 90% from the average session volume of 322,835 shares. The stock had previously closed at $31.75.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. B. Riley cut their price target on shares of Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a report on Wednesday, December 4th. HC Wainwright initiated coverage on shares of Harrow in a research report on Thursday, February 6th. They set a "buy" rating and a $57.00 price objective for the company.

Harrow Price Performance

The stock's fifty day moving average price is $33.96 and its two-hundred day moving average price is $39.97. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Hedge Funds Weigh In On Harrow

Several institutional investors have recently made changes to their positions in the business. First Turn Management LLC purchased a new stake in Harrow during the 3rd quarter valued at approximately $14,683,000. JPMorgan Chase & Co. lifted its position in shares of Harrow by 443.1% during the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock worth $10,717,000 after purchasing an additional 194,480 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Harrow during the third quarter worth $8,572,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company's stock valued at $11,313,000 after acquiring an additional 166,602 shares in the last quarter. Finally, Braidwell LP raised its holdings in shares of Harrow by 47.9% in the third quarter. Braidwell LP now owns 439,638 shares of the company's stock valued at $19,766,000 after acquiring an additional 142,450 shares in the last quarter. Institutional investors own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.